AMETEK heads into its Q1 2026 earnings today with investors more constructive than cautious — and the data largely backs that confidence up.
Options positioning is the clearest tell. The put/call ratio has eased to 0.48, well below its 20-day average of 0.54, making it one of the more call-leaning reads of the past month. That shift follows a strong recovery in the stock: AMETEK rose 13% over the past month to close at $235.50 on April 30, including a 3.3% jump in yesterday's session. The borrow market adds to the benign picture. Availability remains extremely loose, with cost to borrow at just 0.34% APR — well below even typical GC rates — and short interest a modest 1.4% of the free float. Short sellers have added some exposure over the past month, up roughly 15%, but from a negligible base. There is no meaningful short-side pressure heading into the print.
The bull case centers on execution and backlog. AMETEK carries a record order backlog and a track record of steady compounding: last quarter posted 11.3% year-on-year revenue growth with an EBITDA margin above 32%. Free cash flow conversion has historically been strong, and the company's acquisition playbook remains a credible lever for further earnings growth. Bears point to the industrial macro, where tariff uncertainty is weighing on customer capital spending across the sector — a risk that is real even if AMETEK's niche, high-margin product mix offers some insulation. Analyst sentiment is split between cautious neutrals and genuine bulls. Baird trimmed its target to $235 in late March while holding Neutral; BMO initiated at Outperform with a $253 target around the same time; Morgan Stanley nudged its Equal-Weight target up to $235 in mid-March. The mean consensus target is $253, about 7% above the current price. The picture is not one of conviction on either side — more a stock where the Street respects the quality but is divided on how much the macro headwind will clip near-term numbers.
Peer performance into the print has been mixed in a way that complicates the setup. EMR and ETN both gained roughly 3-5% on the day, while HUBB fell almost 7% on the week — a reminder that industrial earnings reactions have been wide in this environment. ROK was flat on the week. The dispersion in outcomes across close correlated names suggests markets are differentiating sharply on guidance and mix rather than re-rating the group.
The print will therefore test whether AMETEK's margin profile and backlog have remained durable enough to offset any macro softness — and, critically, whether management's guidance speaks to tariff exposure in a way that satisfies a market that has been quick to sell industrial names that disappoint on that front.
See the live data behind this article on ORTEX.
Open AME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
